logo
Plus   Neg
Share
Email

Biolase Technology Slips To Loss In Q4

Biolase Technology, Inc. (BLTI) reported Thursday a fourth-quarter net loss of $2.0 million or $0.06 per share, compared to net income of $174,000 or $0.01 per share last year.

Excluding iems, non-GAAP net loss was $1.3 million or $0.04 per share, compared to non-GAAP net income of $0.9 million or $0.04 per share.

On average, 5 analysts polled by Thomson Reuters expected the company to report a loss of $0.02 per share for the quarter. Analysts' estimates typically exclude one-time items.

Net revenue for the quarter rose 36 percent to $13.2 million from $9.7 million last year, primarily driven by Biolase's exit from an exclusive distribution arrangement in August 2010 with Henry Schein,Inc.(HSIC) and the company's return to a direct sales and selected-distributor business model. Analysts expected revenues of $13.10 million.


Looking forward, the company expects revenue of approximately $11 million for the first quarter of fiscal 2012, Analysts expect first quarter revenue of $13.23 million. For the full year 2012, the company expects revenue of $57 million-$60 million . Analysts expect revenue of $66.31 million for the full year 2012.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

More Breaking News

Editors Pick
An administrative law judge has ruled that Minnesota regulators should approve Enbridge Inc.'s proposal to replace its aging Line 3 crude oil pipeline only if the company follows the existing route and not its preferred route. Enbridge has applied to replace its Line 3 pipeline from Alberta with new pipe along its existing route. In Minnesota, the planned route deviates from the existing route. CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV... Most Americans have access to health care, though costs and services vary from state to state. However, higher costs do not necessarily translate into better results. The U.S. continues to be outperformed by other wealthy nations on several measures like life expectancy, disease burden and health...
Follow RTT